冠状动脉内给予坎格雷洛辅助原发性经皮冠状动脉介入治疗一名原发性血小板增多症合并复发性ST段抬高型心肌梗死患者。 - Suppr

Suppr

超能文献

Intracoronary cangrelor administration-assisted primary percutaneous coronary intervention in a patient with essential thrombocythemia and recurrent ST-segment elevation myocardial infarction.

作者信息

Ielasi Alfonso, Loffi Marco, Buono Andrea, De Blasio Giuseppe, Tespili Maurizio

机构信息

Clinical and Interventional Cardiology Unit, Sant'Ambrogio Cardio-Thoracic Center GSD, Milan.

Cardiology Unit, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona.

出版信息

J Cardiovasc Med (Hagerstown). 2020 Oct;21(10):825-828. doi: 10.2459/JCM.0000000000001006.

DOI:10.2459/JCM.0000000000001006

PMID:32740411

Abstract

摘要

相似文献

Intracoronary cangrelor administration-assisted primary percutaneous coronary intervention in a patient with essential thrombocythemia and recurrent ST-segment elevation myocardial infarction.

J Cardiovasc Med (Hagerstown). 2020 Oct;21(10):825-828. doi: 10.2459/JCM.0000000000001006.

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Circulation. 2019 Apr 2;139(14):1661-1670. doi: 10.1161/CIRCULATIONAHA.118.038317.

Resolution of Massive Intracoronary Thrombus During Percutaneous Coronary Intervention Utilizing Intensive Pharmacological and Aspiration Strategies.

Cardiovasc Revasc Med. 2020 Feb;21(2):251-253. doi: 10.1016/j.carrev.2019.12.017. Epub 2019 Dec 14.

Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.

Circulation. 2020 Aug 4;142(5):441-454. doi: 10.1161/CIRCULATIONAHA.120.046928. Epub 2020 Jun 27.

Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.

JACC Cardiovasc Interv. 2016 Sep 26;9(18):1905-13. doi: 10.1016/j.jcin.2016.06.046.

Impact of Cangrelor on Coronary Thrombus: Optical Coherence Tomography Assessment.

Cardiovasc Revasc Med. 2020 May;21(5):700-701. doi: 10.1016/j.carrev.2020.01.021. Epub 2020 Jan 30.

Discontinuation of both cangrelor and ticagrelor because of severe dyspnea during primary angioplasty.

J Cardiovasc Med (Hagerstown). 2021 Apr 1;22(4):317-319. doi: 10.2459/JCM.0000000000001042.

Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.

Am Heart J. 2012 May;163(5):768-776.e2. doi: 10.1016/j.ahj.2012.02.018.

Cangrelor: A Review in Percutaneous Coronary Intervention.

Drugs. 2015 Aug;75(12):1425-34. doi: 10.1007/s40265-015-0445-3.

The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.

Eur Heart J. 2016 Apr 7;37(14):1122-30. doi: 10.1093/eurheartj/ehv498. Epub 2015 Sep 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Intracoronary cangrelor administration-assisted primary percutaneous coronary intervention in a patient with essential thrombocythemia and recurrent ST-segment elevation myocardial infarction.

作者信息

Ielasi Alfonso, Loffi Marco, Buono Andrea, De Blasio Giuseppe, Tespili Maurizio

机构信息

Clinical and Interventional Cardiology Unit, Sant'Ambrogio Cardio-Thoracic Center GSD, Milan.

Cardiology Unit, Azienda Socio Sanitaria Territoriale (ASST) di Cremona, Cremona.

出版信息

J Cardiovasc Med (Hagerstown). 2020 Oct;21(10):825-828. doi: 10.2459/JCM.0000000000001006.

DOI:10.2459/JCM.0000000000001006

PMID:32740411

Abstract

摘要

相似文献

Intracoronary cangrelor administration-assisted primary percutaneous coronary intervention in a patient with essential thrombocythemia and recurrent ST-segment elevation myocardial infarction.

J Cardiovasc Med (Hagerstown). 2020 Oct;21(10):825-828. doi: 10.2459/JCM.0000000000001006.

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Circulation. 2019 Apr 2;139(14):1661-1670. doi: 10.1161/CIRCULATIONAHA.118.038317.

Resolution of Massive Intracoronary Thrombus During Percutaneous Coronary Intervention Utilizing Intensive Pharmacological and Aspiration Strategies.

Cardiovasc Revasc Med. 2020 Feb;21(2):251-253. doi: 10.1016/j.carrev.2019.12.017. Epub 2019 Dec 14.

Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.

Circulation. 2020 Aug 4;142(5):441-454. doi: 10.1161/CIRCULATIONAHA.120.046928. Epub 2020 Jun 27.

JACC Cardiovasc Interv. 2016 Sep 26;9(18):1905-13. doi: 10.1016/j.jcin.2016.06.046.

Impact of Cangrelor on Coronary Thrombus: Optical Coherence Tomography Assessment.

Cardiovasc Revasc Med. 2020 May;21(5):700-701. doi: 10.1016/j.carrev.2020.01.021. Epub 2020 Jan 30.

Discontinuation of both cangrelor and ticagrelor because of severe dyspnea during primary angioplasty.

J Cardiovasc Med (Hagerstown). 2021 Apr 1;22(4):317-319. doi: 10.2459/JCM.0000000000001042.

Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.

Am Heart J. 2012 May;163(5):768-776.e2. doi: 10.1016/j.ahj.2012.02.018.

Cangrelor: A Review in Percutaneous Coronary Intervention.

Drugs. 2015 Aug;75(12):1425-34. doi: 10.1007/s40265-015-0445-3.

The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.

Eur Heart J. 2016 Apr 7;37(14):1122-30. doi: 10.1093/eurheartj/ehv498. Epub 2015 Sep 23.